stapokibatrt
mAbexperimental
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
2
Phase 3
2
Phase 4
0
Earliest trial started May 31, 2025 (NCT06956196)
Timeline
2020s
- Jan 1, 2025
Earliest Phase 3 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Interleukin-4 receptor subunit alphaINHIBITOR
IL4R inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07106372 | Phase 3 | Sep 30, 2025 | Capital Medical University, Keymed Biosciences Co.Ltd |
| NCT06956196 | Phase 3 | May 31, 2025 | Capital Medical University, Keymed Biosciences Co.Ltd |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Capital Medical University | Academic/Hospital | 2 | 0 | 1 | 2025 |
| Keymed Biosciences Co.Ltd | For profit | 2 | 2 | 1 | 2025 |
2 organizations
Page 1 / 1